Global In-vitro Inflammatory Bowel Disease Diagnostic and Treatment Market Outlook 2028

Inflammatory bowel disease (IBD) is characterized by the inflammation of the gastrointestinal tract. The exact cause of the disease is yet unknown and prevention from the disease can only save an individual. There are two types of IBD, namely, Crohn’s disease and ulcerative colitis. The global in-vitro inflammatory bowel disease (IBD) market is anticipated to grow with a CAGR of 5.4% over the forecast period, i.e., 2021 - 2028. Factors such as the growing incidences of the disease globally, followed by the increasing awareness about the disease amongst individuals, and the favorable initiatives of the government of nations for the advancements in research in the field of gastro sciences, are anticipated to drive the market growth. The market is estimated to garner a revenue of about USD 2390 Million by the end of 2028, up from close to USD 1640 Million in 2019.

The global in-vitro inflammatory bowel disease (IBD) market is segmented by numerous segments, which include segmentation by product, disease type, disease stage, test type, patient demography, end user, test method, and by region. The market is segmented by product into assays/biomarkers and analyzers, out of which, the assays/biomarkers segment is anticipated to grow with the highest CAGR of close to 6% and also hold the highest market share during the forecast period. Moreover, the market is also segmented on the basis of test type into blood tests, stool tests, antibody tests, and biopsy. Out of these, the blood tests segment is anticipated to hold the highest market share and also attain a market revenue of around USD 930 Million by the end of 2028.

The global in-vitro inflammatory bowel disease (IBD) market is segmented on the basis of region into North America, Europe, Asia Pacific, Latin America and Middle East & Africa region, out of which, the market in North America is anticipated to garner the largest market revenue of USD 1070 Million approximately by the end of 2028, up from about USD 720 Million in the year 2019.

Some of the prominent industry leaders in the global in-vitro inflammatory bowel disease (IBD) market that are included in our report are DiaSorin S.p.A., American Laboratory Products Company, Ltd. (d/b/a ALPCO Diagnostics), Quidel Corporation, CerTest Biotec, S.L., BUHLMANN Laboratories AG, BioSystems S.A., Inova Diagnostics, Inc. (Werfen), and others.